ArticleAnnals of medicine2026
Association of elevated homocysteine levels with renal pathology and function in patients with IgA nephropathy: a single-center retrospective study.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe role of homocysteine (Hcy) in immunoglobulin A nephropathy (IgAN) remains unclear. This study investigates the association between Hcy levels, clinical symptoms, and pathological changes in patients with IgAN to elucidate Hcy's clinical significance.
methods256 IgAN patients were included and categorized into two groups : normal Hcy and hyperhomocysteinemia (HHcy). Clinical and pathological characteristics were compared between these groups. Logistic regression was used to analyze the association between clinicopathological factors and Hcy levels, while the predictive capability of Hcy for renal tubular atrophy/interstitial fibrosis was evaluated using receiver operating characteristic (ROC) curve analysis.
resultsThe average age of participants was 41.01 ± 12.83 years; 58.6% were male, and 32% had HHcy. Patients with HHcy showed higher rates of hypertension and increased levels of serum creatinine, 24-hour urinary protein, urinary albumin-creatinine ratio, retinol-binding protein, cystatin C, urinary neutrophil gelatinase-associated lipocalin, beta2-microglobulin, serum potassium, serum phosphate, and parathyroid hormone. They also exhibited more severe tubular atrophy/interstitial fibrosis. In contrast, they had lower estimated glomerular filtration rate, hemoglobin, and HDL cholesterol levels. No significant differences were observed in mesangial hypercellularity, endocapillary hypercellularity, focal segmental glomerulosclerosis, and crescents scores between the groups. Hcy levels correlated significantly with the severity of tubular/interstitial fibrosis, serving as a modest predictor with an exploratory optimal cutoff value of 12.50 μmol/L [AUC = 0.756 (95% CI: 0.686-0.824,
conclusionsElevated Hcy levels are associated with pathological severity and worse kidney function in IgAN patients. However, this association was largely attenuated after adjusting for renal function, and the AUC of 0.756 indicates only modest discriminative ability. Hcy should be used together with other clinical and pathological markers, not as a standalone prognostic tool. Whether lowering Hcy levels can modify IgAN progression remains to be determined in prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.